Bryan McKibben

Medicinal Chemistry

Bryan McKibben has over 20 years of experience as a medicinal chemist. Bryan started his career in biotech with Cadus Pharmaceuticals which was subsequently bought by OSI Pharmaceuticals. He later joined Boehringer-Ingelheim Pharmaceuticals and worked in immunology / inflammatory drug discovery. Currently, Bryan is Project Director (Principal Scientist II) in Drug Discovery at AbbVie where he leads a team of interdisciplinary scientists. Over his career, Bryan played a key role in advancing multiple compounds into clinical trials. Bryan was trained as a synthetic organic chemist. He received a PhD with Professor Tomas Hudlicky at Virginia Tech, followed by a postdoctoral fellowship with Professor Victor Snieckus at the University of Waterloo.

GDC-2394

GDC-2394 (Genentech) is an oral NLRP3 inflammasome inhibitor. The NLRP3 inflammasome is the best studied and most characterized inflammasome , with the protein playing a key role in the detection of inflammatory danger signals which are a hallmark of many inflammatory diseases. Hyperactivation of the NLRP3 has been implicated in the [...]

Molecule

Drug Hunter Letters #3 - September 2022

This edition of Drug Hunter Letters highlights recent insightful communications from Drug Hunter readers, including: Simon Bury on the History of GSK’s Recently Acquired $1.9B JAK Inhibitor Callie Bryan and Bryan McKibben on Insulin Receptor Partial Agonists and Recent Oncology Highlights Jesse Keicher on CXCR1/2 Antagonists in Treating [...]

Article

compound 20

Context. “Compound 20” (Gedeon Richter) is an oral α5-GABA A receptor negative allosteric modulator (NAM) being developed for cognitive disorders . GABA receptor NAMs are known to exert effects opposite to the anxiolytic and anticonvulsant effects of positive allosteric modulators. However, NAM agents targeting α5-GABA A receptors, which have [...]

Molecule

rilzabrutinib (PRN1008)

PRN1008 (rilzabrutinib, Sanofi) is an oral, reversible covalent Bruton’s tyrosine kinase (BTK) inhibitor in a Ph. III trial for immune thrombocytopenia. A simultaneously published inhibitor, PRN473, is in development as a topical treatment for atopic dermatitis. Following target discovery in 1993, and subsequent approval of the first [...]

Molecule

HR1405-01

Context. HR1405-01 (Nanjing Heron Pharmaceutical) is an intravenous NSAID with inflammatory and analgesic activities. Oral NSAIDs (ibuprofen, naproxen..) are widely used, and it is interesting to see justification for a new intravenous NSAID. Intravenous ibuprofen was the first intravenous NSAID to be approved, following which a couple of [...]

Molecule

compound 14f

Compound 14f (Kyowa Kirin) is an oral ChemR23 inhibitor with two acidic sites. Nominated by Bryan McKibben , this article describes a scaffold hopping exercise to address the short half-life of previously described chemical matter, and the successful development of in-vivo tool inhibitors to probe ChemR23 biology in animal models of [...]

Molecule

Join the Drug Hunter Mailing List

to get free content and resources weekly. Trusted by >8,000 drug hunters worldwide. Unsubscribe anytime.